Human Granzyme B Precoated ELISA Kit
$499.00
Out of stock
In-stock products will arrive in 1 to 2 business days
Key Features
✓ Assay Range: 31.3-2000 pg/mL
✓ Sensitivity: 15 pg/mL
✓ Sample Types: Serum, Plasma, Cell Culture Supernates
Size
✓ 1 Kit (96 well plate)
Need Help Ordering?
Product Details
Storage & Preparation
Data Images
Background
Product Documents
Product Details
| Product Type | Quantitative ELISA, Colorimetric |
| Product Summary |
|
| Reactivity | Human Granzyme B
|
| Product Components |
|
Storage & Preparation
| Shipping | Shipped on blue ice |
| Stability & Storage | Store the unopened kit at 2-8℃, The kit is stable for 12 months. Do not use beyond expiration date. |
| Reconstitution | See Datasheet for Component Preparation |
Data Images
Human Granzyme B ELISA standard curve, typical data. User-generated standard curve is required for each set of samples. Please refer to protocol.
Background
| Alternative Names | GZMB, C11, CCPI, Cathepsin G-like 1, CGL1, CSPB, CTSGL1, Cytotoxic T-lymphocyte proteinase 2, Fragmentin-2, Granzyme-2, Human Lymphocyte Protein, HLP, SECT, T-cell serine protease 1-3E |
| Function | Granzyme B is a serine protease produced primarily by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, playing a role in the immune system’s ability to eliminate infected or transformed cells. Once delivered into a target cell, granzyme B cleaves and activates a variety of substrates that initiate apoptotic pathways. This includes the activation of caspase enzymes (like caspase-3) and the cleavage of Bid, a pro-apoptotic Bcl-2 family member, which together help trigger mitochondrial damage and cell death. Granzyme B can induce cell death by both caspase-dependent mechanisms and caspase-independent mechanisms. Granzyme B has been found to contribute to extracellular matrix remodeling and inflammation under certain pathological conditions. It is initially synthesized as an inactive precursor (zymogen) containing an N-terminal signal peptide and a propeptide segment. Proteolytic removal of the propeptide is necessary to generate the active enzyme. |
| Tissue Specificity | Granzyme B is primarily expressed in cytotoxic T lymphocytes (CD8+ T cells) and natural killer (NK) cells. Within cytotoxic cells, Granzyme B is predominantly localized in secretory granules. Granzyme B has been reported in secondary lymphoid tissues such as lymph nodes, spleen, and tonsils. |
| Cellular Localization | Secreted protein, localized in secretory granules prior to release. |
| Involvement in Disease | Dysregulation of Granzyme B has been reported in autoimmune diseases (type I diabetes, rheumatoid arthritis, systemic lupus erythematosus (SLE), and multiple sclerosis, chronic viral infections (HIV, hepatitis), tumor microenvironment, and atherosclerosis. |
| UniProt | P10144 |
| Gene Symbol | GZMB |
| Entrez Gene ID | 3002 |
Product Documents
| Product Datasheet | Download Product Datasheet |
| COA | Contact Us |
| SDS | Contact Us |
Reviews
There are no reviews yet.